892 related articles for article (PubMed ID: 36028120)
1. MicroRNAs in non-alcoholic fatty liver disease: Progress and perspectives.
Hochreuter MY; Dall M; Treebak JT; Barrès R
Mol Metab; 2022 Nov; 65():101581. PubMed ID: 36028120
[TBL] [Abstract][Full Text] [Related]
2. Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
Johnson K; Leary PJ; Govaere O; Barter MJ; Charlton SH; Cockell SJ; Tiniakos D; Zatorska M; Bedossa P; Brosnan MJ; Cobbold JF; Ekstedt M; Aithal GP; Clément K; Schattenberg JM; Boursier J; Ratziu V; Bugianesi E; Anstee QM; Daly AK; ;
JHEP Rep; 2022 Feb; 4(2):100409. PubMed ID: 35072021
[TBL] [Abstract][Full Text] [Related]
3. miRNAs in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Liu CH; Ampuero J; Gil-Gómez A; Montero-Vallejo R; Rojas Á; Muñoz-Hernández R; Gallego-Durán R; Romero-Gómez M
J Hepatol; 2018 Dec; 69(6):1335-1348. PubMed ID: 30142428
[TBL] [Abstract][Full Text] [Related]
4. Circulating miRNAs associated with nonalcoholic fatty liver disease.
Atic AI; Thiele M; Munk A; Dalgaard LT
Am J Physiol Cell Physiol; 2023 Feb; 324(2):C588-C602. PubMed ID: 36645666
[TBL] [Abstract][Full Text] [Related]
5. Exosomal miR-122, miR-128, miR-200, miR-298, and miR-342 as novel diagnostic biomarkers in NAFL/NASH: Impact of LPS/TLR-4/FoxO3 pathway.
Samy AM; Kandeil MA; Sabry D; Abdel-Ghany AA; Mahmoud MO
Arch Pharm (Weinheim); 2024 Apr; 357(4):e2300631. PubMed ID: 38574101
[TBL] [Abstract][Full Text] [Related]
6. Disease-specific miR-34a as diagnostic marker of non-alcoholic steatohepatitis in a Chinese population.
Liu XL; Pan Q; Zhang RN; Shen F; Yan SY; Sun C; Xu ZJ; Chen YW; Fan JG
World J Gastroenterol; 2016 Nov; 22(44):9844-9852. PubMed ID: 27956809
[TBL] [Abstract][Full Text] [Related]
7. Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review.
Kan Changez MI; Mubeen M; Zehra M; Samnani I; Abdul Rasool A; Mohan A; Wara UU; Tejwaney U; Kumar V
J Int Med Res; 2023 Sep; 51(9):3000605231197058. PubMed ID: 37676968
[TBL] [Abstract][Full Text] [Related]
8. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
[TBL] [Abstract][Full Text] [Related]
9. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis.
Pirola CJ; Fernández Gianotti T; Castaño GO; Mallardi P; San Martino J; Mora Gonzalez Lopez Ledesma M; Flichman D; Mirshahi F; Sanyal AJ; Sookoian S
Gut; 2015 May; 64(5):800-12. PubMed ID: 24973316
[TBL] [Abstract][Full Text] [Related]
10. Circulating microRNA expression and nonalcoholic fatty liver disease in adolescents with severe obesity.
Li YJ; Baumert BO; Stratakis N; Goodrich JA; Wu HT; He JX; Zhao YQ; Aung MT; Wang HX; Eckel SP; Walker DI; Valvi D; La Merrill MA; Ryder JR; Inge TH; Jenkins T; Sisley S; Kohli R; Xanthakos SA; Baccarelli AA; McConnell R; Conti DV; Chatzi L
World J Gastroenterol; 2024 Jan; 30(4):332-345. PubMed ID: 38313232
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis.
Shen Y; Cheng L; Xu M; Wang W; Wan Z; Xiong H; Guo W; Cai M; Xu F
Metabolism; 2023 Sep; 146():155657. PubMed ID: 37422021
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis.
Su Q; Kumar V; Sud N; Mahato RI
Adv Drug Deliv Rev; 2018 Apr; 129():54-63. PubMed ID: 29391222
[TBL] [Abstract][Full Text] [Related]
13. A Series of microRNA in the Chromosome 14q32.2 Maternally Imprinted Region Related to Progression of Non-Alcoholic Fatty Liver Disease in a Mouse Model.
Okamoto K; Koda M; Okamoto T; Onoyama T; Miyoshi K; Kishina M; Kato J; Tokunaga S; Sugihara TA; Hara Y; Hino K; Murawaki Y
PLoS One; 2016; 11(5):e0154676. PubMed ID: 27135827
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
15. A micro-RNA expression signature for human NAFLD progression.
Guo Y; Xiong Y; Sheng Q; Zhao S; Wattacheril J; Flynn CR
J Gastroenterol; 2016 Oct; 51(10):1022-30. PubMed ID: 26874844
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Fang Z; Dou G; Wang L
Int J Biol Sci; 2021; 17(7):1851-1863. PubMed ID: 33994867
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-223 Ameliorates Nonalcoholic Steatohepatitis and Cancer by Targeting Multiple Inflammatory and Oncogenic Genes in Hepatocytes.
He Y; Hwang S; Cai Y; Kim SJ; Xu M; Yang D; Guillot A; Feng D; Seo W; Hou X; Gao B
Hepatology; 2019 Oct; 70(4):1150-1167. PubMed ID: 30964207
[TBL] [Abstract][Full Text] [Related]
18. Role of microRNAs in alcohol-induced liver disorders and non-alcoholic fatty liver disease.
Torres JL; Novo-Veleiro I; Manzanedo L; Alvela-Suárez L; Macías R; Laso FJ; Marcos M
World J Gastroenterol; 2018 Sep; 24(36):4104-4118. PubMed ID: 30271077
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte miR-34a is a key regulator in the development and progression of non-alcoholic fatty liver disease.
Xu Y; Zhu Y; Hu S; Pan X; Bawa FC; Wang HH; Wang DQ; Yin L; Zhang Y
Mol Metab; 2021 Sep; 51():101244. PubMed ID: 33930596
[TBL] [Abstract][Full Text] [Related]
20. MicroRNAs and Nonalcoholic Steatohepatitis: A Review.
Morishita A; Oura K; Tadokoro T; Fujita K; Tani J; Kobara H; Ono M; Himoto T; Masaki T
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
